BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

Despite having one of the lowest survival rates of all cancers, there have been no new approved treatments for malignant pleural mesothelioma (MPM) in over a decade. Standard-of-care treatment relies on Cisplatin plus Pemetrexed chemotherapy. Here, we tested a suite of BH3-mimetic drugs targeting BC...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Death Discov
Autori principali: Arulananda, Surein, O’Brien, Megan, Evangelista, Marco, Harris, Tiffany J., Steinohrt, Nikita S., Jenkins, Laura J., Walkiewicz, Marzena, O’Donoghue, Robert J. J., Poh, Ashleigh R., Thapa, Bibhusal, Williams, David S., Leong, Trishe, Mariadason, John M., Li, Xia, Cebon, Jonathan, Lee, Erinna F., John, Thomas, Fairlie, W. D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7603509/
https://ncbi.nlm.nih.gov/pubmed/33298868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41420-020-00348-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi